Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
19.2M
-
Shares change
-
-131K
-
Total reported value, excl. options
-
$174M
-
Value change
-
-$251K
-
Put/Call ratio
-
1.77
-
Number of buys
-
38
-
Number of sells
-
-39
-
Price
-
$9.05
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2016
106 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q3 2016.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.2M shares
of 236M outstanding shares and own 8.14% of the company stock.
Largest 10 shareholders include EAGLE ASSET MANAGEMENT INC (3.51M shares), Nantahala Capital Management, LLC (1.92M shares), FIRST MANHATTAN CO (1.71M shares), BlackRock Fund Advisors (1.51M shares), VANGUARD GROUP INC (1.15M shares), venBio Select Advisor LLC (945K shares), FMR LLC (932K shares), PERCEPTIVE ADVISORS LLC (809K shares), BlackRock Institutional Trust Company, N.A. (777K shares), and ACUTA CAPITAL PARTNERS, LLC (700K shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.